Search

Displaying results 5641 - 5650 of 10000 in total
  1. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  2. Drug

    Pimodivir

    go.drugbank.com/drugs/DB14974
    Investigational

    Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).

  3. Drug

    Foscenvivint

    go.drugbank.com/drugs/DB15034
    Investigational

    PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).

  4. Drug

    Ravoxertinib

    go.drugbank.com/drugs/DB15281
    Investigational

    Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).

  5. Drug

    BI 2536

    go.drugbank.com/drugs/DB16107
    Investigational

    BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).

  6. Drug

    Tromantadine

    go.drugbank.com/drugs/DB13288
    Approved

    It is an antiviral used in the treatment of herpes zoster and simplex.

  7. Drug

    Dopexamine

    go.drugbank.com/drugs/DB12313
    ApprovedWithdrawn

    Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.

  8. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    Nevadistinel has a monoisotopic molecular weight of 274.13 Da. … Nevadistinel is under investigation in clinical trial NCT04148391 (NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory

  9. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  10. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.